Participant flow

Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer · Source last updated 2025-04-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT. External Beam Radiation Therapy: Undergo External Beam Radiation Therapy Metformin Hydrochloride: Given orally

   id

   FG000

   title

   Arm I (EBRT, Metformin Hydrochloride)

2. description

   Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT. External Beam Radiation Therapy: Undergo External Beam Radiation Therapy Placebo: Given orally

   id

   FG001

   title

   Arm II (EBRT, Placebo)

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         5

      2. group Id

         FG001

         num Subjects

         4

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         5

      2. group Id

         FG001

         num Subjects

         4

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice